Analysts expect XORTX Therapeutics Inc. to report revenue of 0.00 for 2023, against a range of 0.00 to 0.00. The most recent reported year, 2022, came in at 0.00.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | - | - | |||
| High Estimate | 0.00 | 0.00 | 0.00 | 3.04 M | |||
| Low Estimate | 0.00 | 0.00 | 0.00 | 2.61 M | |||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 2.82 M |
Analysts expect XORTX Therapeutics Inc. to report earnings per share of -0.41 for Q3 26, against a range of -0.43 to -0.39. The most recent reported quarter, Q2 26, came in at -1.05.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.45 | -0.20 | -0.95 | -0.95 | -0.65 | -0.25 | -0.58 | -1.05 | - | - | - | - | - | - | - | - | ||
| High Estimate | -1.75 | -1.31 | -1.19 | -1.09 | -0.72 | -0.86 | - | - | -0.39 | 0.11 | 0.72 | 0.48 | 1.15 | 2.01 | 1.22 | 0.56 | ||
| Low Estimate | -1.99 | -1.49 | -1.33 | -1.27 | -0.88 | -0.92 | - | - | -0.43 | 0.09 | 0.62 | 0.42 | 0.97 | 1.69 | 1.08 | 0.50 | ||
| Consensus Estimate | -1.87 | -1.40 | -1.26 | -1.18 | -0.80 | -0.89 | - | - | -0.41 | 0.10 | 0.67 | 0.45 | 1.06 | 1.85 | 1.15 | 0.53 |
Pull Wall Street consensus for XORTX Therapeutics Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=XRTX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "XRTX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=XRTX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();